TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05755555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit a doctor
Description: Test messages based on concepts from behavioural economics that aim to make information on screening more salient by using the concept of social proof (person like you) and an authoritative source (a diabetes specialist)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit a doctor
Description: Test messages based on concepts from behavioural economics that aim to make information on screening more salient by using the concept of social proof (person like you) and an authoritative source (a diabetes specialist)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visit a doctor
Description: Test messages based on concepts from behavioural economics that aim to make information on screening more salient by using the concept of social proof (person like you) and an authoritative source (a diabetes specialist)
Study: NCT06506994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-9057
Description: HRS-9057 injection dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-9057
Description: HRS-9057 injection dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan tablets
Study: NCT04943692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin glycinate
Description: 1050 mg, tablets Administered orally, twice a day, for 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: 850 mg, tablets. Administered orally, twice a day, for 12 months.
Study: NCT06025799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction intervention
Description: The Mindfulness-Based Stress Reduction (MBSR) program consists of eight sessions focusing on reducing stress and improving well-being. Participants learn and practice mindfulness techniques such as mindful eating, breathing, body scan, and meditation. The program emphasizes self-responsibility, developing coping strategies, and applying mindfulness daily. Participants engage in formal mindfulness practices, reflect on their experiences, and receive guidance on continuing their mindfulness journey after the program. The goal is to cultivate resilience, enhance well-being, and reduce stress.
Study: NCT05957029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NuEra Tight RF system
Description: monopolar radiofrequency device
Study: NCT05796141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss (BWL) intervention
Description: Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss (BWL) intervention
Description: Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss (BWL) intervention
Description: Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss (BWL) intervention
Description: Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss (BWL) intervention
Description: Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)
Study: NCT05844189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRMRF
Description: CRMRF application on pelvic floor:~* Externally over the urogenital triangle of the patient,~* Intracavitary application (intravaginal)~* Externally over the urogenital triangle of the patient while the physical therapist performs the intracavitary manual therapy (intravaginal),~The device used is named Intradermik and it is the portable CRMRF device of the brand RÖS'S Estética SL.~It has these features:~* Frequency: 448kHz~* Capacitive power: 450 voltamperes~* Resistive power: 200 watts

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CRMRF
Description: The physical therapist applies the same treatment as the Treatment Group but the device is switched off.
Study: NCT05221333

Intervention type: DEVICE
Group type: OTHER
Intervention: Sorrel Wearable Injector
Description: Use of Sorrel Wearable Injector in pilot study
Study: NCT05796141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss (BWL) intervention
Description: Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss (BWL) intervention
Description: Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss (BWL) intervention
Description: Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss (BWL) intervention
Description: Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss (BWL) intervention
Description: Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss (BWL) intervention
Description: Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss (BWL) intervention
Description: Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss (BWL) intervention
Description: Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss (BWL) intervention
Description: Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss (BWL) intervention
Description: Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)
Study: NCT04591340

Intervention type: DIETARY_SUPPLEMENT
Intervention: dietary advice, oral nutritional supplement, supplementary parenteral nutrition or total parenteral nutrition
Description: All HSCT(hematopoietic stem cell transplantation) patients should be accepted dietary advice or oral nutritional supplement, if their energy intake will not reach 60% of the goal level during the transplanting, then supplementary parenteral nutrition or total parenteral nutrition.
Study: NCT06436170

Intervention type: DIAGNOSTIC_TEST
Intervention: OCTA
Description: OCTA is a non invasive diagnostic technique to visualize RPC

Intervention type: DIAGNOSTIC_TEST
Intervention: OCTA
Description: OCTA is a non invasive diagnostic technique to visualize RPC
Study: NCT05796141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Behavioral Weight Loss (BWL) intervention
Description: Behavioral weight loss core (lessons, self weighing, self-monitoring, individual action planning, feedback and progress check ins)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Action Planning
Description: Participants will develop dyadic action plans together.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Action Planning
Description: Participants will develop dyadic action plans together.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Action Planning
Description: Participants will develop dyadic action plans together.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Action Planning
Description: Participants will develop dyadic action plans together.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Action Planning
Description: Participants will develop dyadic action plans together.
Study: NCT04866355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar spine manipulation
Description: Lumbar spine manipulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar spine manipulation
Description: Lumbar spine manipulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine and Ibuprofen
Description: hyoscine (20 mg) and ibuprofen (400 mg) administered by oral via.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine and Ibuprofen
Description: hyoscine (20 mg) and ibuprofen (400 mg) administered by oral via.
Study: NCT05796141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Action Planning
Description: Participants will develop dyadic action plans together.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Action Planning
Description: Participants will develop dyadic action plans together.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Action Planning
Description: Participants will develop dyadic action plans together.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joint Feedback
Description: Participants will see data on their partner's progress, in addition to their own weight and behavioral data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joint Feedback
Description: Participants will see data on their partner's progress, in addition to their own weight and behavioral data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joint Feedback
Description: Participants will see data on their partner's progress, in addition to their own weight and behavioral data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joint Feedback
Description: Participants will see data on their partner's progress, in addition to their own weight and behavioral data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joint Feedback
Description: Participants will see data on their partner's progress, in addition to their own weight and behavioral data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joint Feedback
Description: Participants will see data on their partner's progress, in addition to their own weight and behavioral data.
Study: NCT06110455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training exercises
Description: The 8 week exercise intervention consists of 25 minute group sessions of Neuromuscular training supervised by a physical therapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip and Knee Muscular Strength exercises
Description: The 8 week exercise intervention consists of 25 minute group sessions of progressive resistance training, supervised by a physical therapist.
Study: NCT04628949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aScope™ Duodeno endoscope and aBox™ Duodeno
Description: The aScope™ Duodeno endoscope is a sterile single-use disposable duodenoscope indicated for endoscopic retrograde cholangiopancreatography (ERCP) procedures.The aScope™ Duodeno endoscope is designed to be used with aBox Duodeno, endoscopic accessories and other ancillary equipment for ERCP procedures.~The aBox Duodeno is the console that is necessary for processing the endoscope camera´s video image, regarding the remote switches and output video and recorder data. The aBox Duodeno is designed to be used with the aScope™ Duodeno endoscope.
Study: NCT04512638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Antibiotic treatment is the same in all groups.~Monotherapy for 4 weeks with:~No penicillin contra-indication~* Amoxicillin-clavulanate 875mg tid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~After 4 weeks patients will be switched to consolidation antibiotics:~No penicillin contra-indication~* Amoxicillin 1g bid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~Antibiotic treatment can be discontinued after 4 weeks when the MRONJ lesions has healed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Antibiotic treatment is the same in all groups.~Monotherapy for 4 weeks with:~No penicillin contra-indication~* Amoxicillin-clavulanate 875mg tid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~After 4 weeks patients will be switched to consolidation antibiotics:~No penicillin contra-indication~* Amoxicillin 1g bid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~Antibiotic treatment can be discontinued after 4 weeks when the MRONJ lesions has healed.
Study: NCT06237595

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus nerve stimulation
Description: Electrical stimulation of the vagus nerve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment
Description: Medical treatment for fibromyalgia patients

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combined vagus nerve stimulation and medical treatment
Description: Combination of the two interventions
Study: NCT04512638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Antibiotic treatment is the same in all groups.~Monotherapy for 4 weeks with:~No penicillin contra-indication~* Amoxicillin-clavulanate 875mg tid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~After 4 weeks patients will be switched to consolidation antibiotics:~No penicillin contra-indication~* Amoxicillin 1g bid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~Antibiotic treatment can be discontinued after 4 weeks when the MRONJ lesions has healed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Patients in all treatment groups will be prescribed aqueous chlorhexidine 0.12% tid rinse for 2 weeks, with subsequent switch to 0.05% for the duration of the study or until healing of the MRONJ lesion has occurred.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Description: Patients in all treatment groups will be prescribed aqueous chlorhexidine 0.12% tid rinse for 2 weeks, with subsequent switch to 0.05% for the duration of the study or until healing of the MRONJ lesion has occurred.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Description: Patients in all treatment groups will be prescribed aqueous chlorhexidine 0.12% tid rinse for 2 weeks, with subsequent switch to 0.05% for the duration of the study or until healing of the MRONJ lesion has occurred.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with LPRF
Description: Minimally-invasive surgical treatment, including sequestrectomy, debridement of soft tissue, and application of LPRF membranes before tension-free wound closure is obtained. Marginal resection of all necrotic bone is not part of this treatment strategy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Primary surgical management consisting of the removal of the necrotic bone without excessive resection of healthy bone. Buccal mucoperiosteal flaps will be used to achieve a tension-free mucosal coverage.
Study: NCT05714943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DigiKnowIt News: Teen
Description: Participants will interact with a multimedia educational website that will teach them about pediatric clinical trials, including topics such as participant rights and safety and different types of procedures used in trials, and will provide strategies for parent-teen shared decision-making about clinical trials.
Study: NCT06210490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: Disitamab vedotin (RC48-ADC) is a novel humanized anti-human epidermal growth factor receptor 2 (HER2) antibody conjugated with monomethyl auristatin E via a cleavable linker. Two phase II studies, RC48-C005 (NCT03507166) and RC48-C009 (NCT03809013), have shown its significant antitumor potential in patients with la/mUC with HER2 overexpression (immunohistochemistry (IHC) 3+ or 2+). In 2022, RC48-ADC was approved for patients with HER2 overexpressing la/mUC who had received prior chemotherapy in China.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy dose: 45-50 Gy/25f/5w to lymph node drainage area; 62.5 Gy/25f/5w to metastatic or suspected metastatic lymph nodes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study: NCT05951387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine plus ketamine
Description: titrating the dose of dexmedetomidine mixed with ketamine (staring dose 0.5ug/kg/hr, 0.5mg/kg/hr respectively)to achieve full sedation
Study: NCT05235802

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI) (including functional MRI)
Description: Patients will undergo magnetic resonance imaging including the following protocols:~* 3D T1w MPRAGE~* 3D T2w FLAIR SPACE~* 3D T2w SPACE~* 3D T1w PSIR (cortical visualization)~* 2D synthetic MRI (quantitative T1, T2, PD and myelin quantification)~* Resting-state fMRI (6 min, human connectome protocol, 2 mm iso)~* 3D SWI~* DWI b1000 32 directions and b3000 64 directions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling (serum/plasma preparation)
Description: Blood will be screened for genetic modifications. Serum will be analyzed for auto-antibodies and other inflammatory and neurodegenerative biomarkers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebrospinal fluid (CSF)
Description: CSF will be analyzed for inflammatory and neurodegenerative biomarkers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical assessments / questionnaires
Description: * Glasgow Outcome Scale Extended (functional outcome)~* Short-Form 36 (quality of life),~* EQ-5D (quality of life),~* Mini-Mental State Extended (MMSE) (mental state assessment).~* Barthel Index (daily living disabilities),~* Montgomery-Åsberg Depression Score (MADRS-S) (level of depression)~* Fatigue Severity Scale (FSS) (level of fatigue)~Other than that, neurological assessments focusing on the Unified Parkinson's Disease Rating Scale (UPDRS) will be performed.
Study: NCT05105893

Intervention type: OTHER
Group type: OTHER
Intervention: Dates group
Description: Seven dates to be provided to patients
Study: NCT05796141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joint Feedback
Description: Participants will see data on their partner's progress, in addition to their own weight and behavioral data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joint Feedback
Description: Participants will see data on their partner's progress, in addition to their own weight and behavioral data.
Study: NCT05796141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autonomy Support Training
Description: Participants will receive training in how to create an autonomy supportive environment within their marriage/partnership.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autonomy Support Training
Description: Participants will receive training in how to create an autonomy supportive environment within their marriage/partnership.
Study: NCT05623683

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Walking
Description: Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will walk on the treadmill for 3 blocks of 10 minutes with 2 blocks of 5-minute rest (sitting on a chair) in-between. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Walking
Description: Wearing comfortable clothes and their usual walking shoes, participants will walk on a treadmill to accrue 30 minutes of walking. Participants will be instructed not to use the treadmill side rails for balance or support during walking. Participants will rest for 10 minutes (sitting in a chair) before walking on the treadmill for 1 continuous block of 30 minutes. A safety button to stop the treadmill will be available to the participants, so they can stop walking anytime. If participants feel that they are about to lose balance, they are allowed to hold on to the side rails to regain balance and terminate the trial.
Study: NCT05188677

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2019
Description: a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2019
Description: a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2019
Description: a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2019
Description: a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-2019
Description: a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection
Study: NCT05796141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autonomy Support Training
Description: Participants will receive training in how to create an autonomy supportive environment within their marriage/partnership.